STATE OF NEW JERSEY
217th LEGISLATURE
PRE-FILED FOR INTRODUCTION IN THE 2016 SESSION
Sponsored by:
Assemblyman DANIEL R. BENSON
District 14 (Mercer and Middlesex)
Assemblyman RAJ MUKHERJI
District 33 (Hudson)
Senator LINDA R. GREENSTEIN
District 14 (Mercer and Middlesex)
Senator NILSA CRUZ-PEREZ
District 5 (Camden and Gloucester)
Co-Sponsored by:
Assemblymen C.A.Brown, Caputo, Gusciora and Assemblywoman Downey
SYNOPSIS
Requires health insurance coverage for certain amino acid-based elemental formulas.
CURRENT VERSION OF TEXT
As reported by the Assembly Financial Institutions and Insurance Committee with technical review.
An Act concerning health benefits coverage for amino acid-based elemental formulas, and supplementing Titles 17, 26, and 52 of the Revised Statutes and Title 17B of the New Jersey Statutes.
Be It Enacted by the Senate and General Assembly of the State of New Jersey:
1. A hospital service corporation which provides hospital or medical expense benefits under a contract that is delivered, issued, executed, or renewed in this State or approved for issuance or renewal in this State by the Commissioner of Banking and Insurance, on or after the effective date of this act, shall provide benefits under the contract for expenses incurred for the purchase and administration of amino acid-based elemental formulas, regardless of delivery method, for the treatment of an eosinophilic disorder that has been determined by the covered patient’s physician to be medically necessary. The coverage may be subject to utilization review, including periodic review, of the continued medical necessity of the formula.
The benefits shall be provided to the same extent as for any other medical condition under the contract.
This section shall apply to those hospital service corporation contracts in which the hospital service corporation has reserved the right to change the premium.
2. A medical service corporation which provides hospital or medical expense benefits under a contract that is delivered, issued, executed, or renewed in this State or approved for issuance or renewal in this State by the Commissioner of Banking and Insurance, on or after the effective date of this act, shall provide benefits under the contract for expenses incurred for the purchase and administration of amino acid-based elemental formulas, regardless of delivery method, for the treatment of an eosinophilic disorder that has been determined by the covered patient’s physician to be medically necessary. The coverage may be subject to utilization review, including periodic review, of the continued medical necessity of the formula.
The benefits shall be provided to the same extent as for any other medical condition under the contract.
This section shall apply to those medical service corporation contracts in which the medical service corporation has reserved the right to change the premium.
3. A health service corporation which provides hospital or medical expense benefits under a contract that is delivered, issued, executed, or renewed in this State or approved for issuance or renewal in this State by the Commissioner of Banking and Insurance, on or after the effective date of this act, shall provide benefits under the contract for expenses incurred for the purchase and administration of amino acid-based elemental formulas, regardless of delivery method, for the treatment of an eosinophilic disorder that has been determined by the covered patient’s physician to be medically necessary. The coverage may be subject to utilization review, including periodic review, of the continued medical necessity of the formula.
The benefits shall be provided to the same extent as for any other medical condition under the contract.
This section shall apply to those health service corporation contracts in which the health service corporation has reserved the right to change the premium.
4. An individual health insurer which provides hospital or medical expense benefits under a policy that is delivered, issued, executed, or renewed in this State or approved for issuance or renewal in this State by the Commissioner of Banking and Insurance, on or after the effective date of this act, shall provide benefits under the policy for expenses incurred for the purchase and administration of amino acid-based elemental formulas, regardless of delivery method, for the treatment of an eosinophilic disorder that has been determined by the covered patient’s physician to be medically necessary. The coverage may be subject to utilization review, including periodic review, of the continued medical necessity of the formula.
The benefits shall be provided to the same extent as for any other medical condition under the policy.
This section shall apply to those policies in which the insurer has reserved the right to change the premium.
5. A group health insurer which provides hospital or medical expense benefits under a policy that is delivered, issued, executed, or renewed in this State or approved for issuance or renewal in this State by the Commissioner of Banking and Insurance, on or after the effective date of this act, shall provide benefits under the policy for expenses incurred for the purchase and administration of amino acid-based elemental formulas, regardless of delivery method, for the treatment of an eosinophilic disorder that has been determined by the covered patient’s physician to be medically necessary. The coverage may be subject to utilization review, including periodic review, of the continued medical necessity of the formula.
The benefits shall be provided to the same extent as for any other medical condition under the policy.
This section shall apply to those policies in which the insurer has reserved the right to change the premium.
6. A certificate of authority to establish and operate a health maintenance organization in this State shall not be issued or continued on or after the effective date of this act by the Commissioner of Banking and Insurance unless the health maintenance organization provides health care services in the purchase and administration of amino acid-based elemental formulas, regardless of delivery method, for the treatment of an eosinophilic disorder that has been determined by the covered patient’s physician to be medically necessary. The coverage may be subject to utilization review, including periodic review, of the continued medical necessity of the formula.
The health care services shall be provided to the same extent as for any other medical condition under the contract.
The provisions of this section shall apply to those contracts for health care services by health maintenance organizations under which the health maintenance organization has reserved the right to change the schedule of charges for enrollee coverage.
7. Notwithstanding any other provision of law to the contrary, an individual health benefits plan that is delivered, issued, executed, renewed, or approved for issuance or renewal in this State pursuant to P.L.1992, c.161 (C.17B:27A-2 et seq.), or approved for issuance or renewal in this State by the Commissioner of Banking and Insurance, on or after the effective date of this act, shall provide benefits under the policy for expenses incurred for the purchase and administration of amino acid-based elemental formulas, regardless of delivery method, for the treatment of an eosinophilic disorder that has been determined by the covered patient’s physician to be medically necessary. The coverage may be subject to utilization review, including periodic review, of the continued medical necessity of the formula.
The benefits shall be provided to the same extent as for any other medical condition under the health benefits plan.
This section shall apply to those health benefits plans in which the carrier has reserved the right to change the premium.
8. A small employer health benefits plan that provides hospital and medical expense benefits and is delivered, issued, executed, or renewed in this State pursuant to P.L.1992, c.162 (C.17B:27A-17 et seq.), on or after the effective date of this act, shall provide coverage for medically necessary expenses incurred for the purchase and administration of amino acid-based elemental formulas, regardless of delivery method, for the treatment of an eosinophilic disorder that has been determined by the covered patient’s physician to be medically necessary. The coverage may be subject to utilization review, including periodic review, of the continued medical necessity of the formula.
The benefits shall be provided to the same extent as for any other condition under the health benefits plan.
This section shall apply to those health benefits plans in which the carrier has reserved the right to change the premium.
9. Notwithstanding any other provision of law to the contrary, the State Health Benefits Commission shall ensure that every contract purchased by the commission on or after the effective date of this act that provides hospital or medical expense benefits shall provide benefits under the contract for expenses incurred for the purchase and administration of amino acid-based elemental formulas, regardless of delivery method, for the treatment of an eosinophilic disorder that has been determined by the covered patient’s physician to be medically necessary. The coverage may be subject to utilization review, including periodic review, of the continued medical necessity of the formula.
The benefits shall be provided to the same extent as for any other medical condition under the contract.
10. The School Employees’ Health Benefits Commission shall ensure that every contract purchased by the commission on or after the effective date of this act that provides hospital or medical expense benefits shall provide benefits under the contract for expenses incurred for the purchase and administration of amino acid-based elemental formulas, regardless of delivery method, for the treatment of an eosinophilic disorder that has been determined by the covered patient’s physician to be medically necessary. The coverage may be subject to utilization review, including periodic review, of the continued medical necessity of the formula.
The benefits shall be provided to the same extent as for any other medical condition under the contract.
11. This act shall take effect on the 120th day following enactment and shall apply to policies or contracts issued or renewed on or after that date.